← All trials
NCT06564467
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 23, 2024
- Primary completion
- Jan 10, 2025
- Completion date
- Jul 10, 2025
- First posted
- Aug 21, 2024
- Last posted
- Aug 22, 2024
- Enrollment
- 54
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shanghai JMT-Bio Inc.Lead sponsor
- Peking UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.